Héctor Ortega

12.1k total citations · 4 hit papers
117 papers, 8.6k citations indexed

About

Héctor Ortega is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Héctor Ortega has authored 117 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Physiology, 64 papers in Pulmonary and Respiratory Medicine and 29 papers in Surgery. Recurrent topics in Héctor Ortega's work include Asthma and respiratory diseases (81 papers), Respiratory and Cough-Related Research (50 papers) and Eosinophilic Esophagitis (29 papers). Héctor Ortega is often cited by papers focused on Asthma and respiratory diseases (81 papers), Respiratory and Cough-Related Research (50 papers) and Eosinophilic Esophagitis (29 papers). Héctor Ortega collaborates with scholars based in United States, United Kingdom and Canada. Héctor Ortega's co-authors include Oliver N. Keene, Ian Pavord, Steven W. Yancey, Pascal Chanez, Eugene R. Bleecker, Peter Howarth, Roland Buhl, Stephanie Korn, Lynn E. Katz and Charlene M. Prazma and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Héctor Ortega

103 papers receiving 8.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

2014 1.6k citations Héctor Ortega, Mark C. Liu et al. New England Journal of Medicine profile →
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

2012 1.6k citations Ian Pavord, Peter Howarth et al. profile →
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

2014 1.2k citations Oliver N. Keene, Steven W. Yancey et al. New England Journal of Medicine profile →
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

2016 396 citations Héctor Ortega, Steven W. Yancey et al. profile →

Peers

Countries citing papers authored by Héctor Ortega

Since Specialization

Citations

This map shows the geographic impact of Héctor Ortega's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Héctor Ortega with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Héctor Ortega more than expected).

Fields of papers citing papers by Héctor Ortega

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Héctor Ortega. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Héctor Ortega. The network helps show where Héctor Ortega may publish in the future.

Co-authorship network of co-authors of Héctor Ortega

This figure shows the co-authorship network connecting the top 25 collaborators of Héctor Ortega. A scholar is included among the top collaborators of Héctor Ortega based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Héctor Ortega. Héctor Ortega is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In-vitro Characterization of Solrikitug, A Differentiated Anti-TSLP Antibody, Provides Distinct Epitope Binding Profile and Superior Potency Compared to Tezepelumab 2025 ·American Journal of Respiratory and Critical Care Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), Héctor Ortega	1
2	Chelation-Based Electrochemical Sensor for Histamine Detection 2025 ·Journal of The Electrochemical Society ·(unknown), (unknown), (unknown), Héctor Ortega, (unknown), (unknown), (unknown), (unknown), (unknown)	0
3	Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma 2022 ·CHEST Journal ·Mark H. Moss, Njira Lugogo, Mario Castro, Nicola A. Hanania, Andrea Ludwig-Sengpiel, Dinesh Saralaya, (unknown), Íñigo Ojanguren, (unknown), Jean‐Marie Bruey, Robin Osterhout, (unknown), (unknown), Kartik Raghupathi, Héctor Ortega	5
4	Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs 2020 ·SHILAP Revista de lepidopterología ·(unknown), Héctor Ortega, (unknown), (unknown), (unknown), (unknown), (unknown)	1
5	Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma 2018 ·Journal of Allergy and Clinical Immunology ·Sumita Khatri, Wendy C. Moore, Peter G. Gibson, Richard Leigh, Arnaud Bourdin, Jorge Máspero, (unknown), Roland Buhl, Peter Howarth, Frank C. Albers, Eric Bradford, M Gilson, Robert G. Price, Steven W. Yancey, Héctor Ortega	219
6	Evaluation of the psychometric properties of the St George's Respiratory Questionnaire in patients with severe asthma 2017 ·Respiratory Medicine ·Linda Nelsen, Margaret Vernon, Héctor Ortega, Sarah Cockle, Steven W. Yancey, Guy Brusselle, Frank C. Albers, Paul Jones	8
7	Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study 2016 ·Clinical Therapeutics ·Njira Lugogo, Christian Domingo, Pascal Chanez, Richard Leigh, M Gilson, Robert G. Price, Steven W. Yancey, Héctor Ortega	219
8	Late-breaking abstract: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study 2014 ·European Respiratory Journal ·Héctor Ortega, Mark Liu, Ian Pavord, Guy Brusselle, J. Mark FitzGerald, Alfredo Chetta, Lynn E. Katz, Oliver N. Keene, Steven W. Yancey, Pascal Chanez	1
9	Cluster Analysis and Characterization of Response to Mepolizumab. A Step Closer to Personalized Medicine for Patients with Severe Asthma 2014 ·Annals of the American Thoracic Society ·Héctor Ortega, Hao Li, Robert Suruki, Frank C. Albers, David Gordon, Steven W. Yancey	89
10	Blood Eosinophil Count Is a Useful Biomarker to Identify Patients with Severe Eosinophilic Asthma 2014 ·Annals of the American Thoracic Society ·Lynn E. Katz, Gerald J. Gleich, Benjamin Hartley, Steven W. Yancey, Héctor Ortega	161
11	Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma breakdown → 2014 ·New England Journal of Medicine ·Héctor Ortega, Mark C. Liu, Ian Pavord, Guy Brusselle, J. Mark FitzGerald, Alfredo Chetta, Marc Humbert, Lynn E. Katz, Oliver N. Keene, Steven W. Yancey, Pascal Chanez	1591
12	Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma 2013 ·European Respiratory Journal ·Héctor Ortega, Lynn E. Katz, Benjamin Hartley, Steve Yancey	1
13	Long-term Safety And Efficacy Of Mepolizumab For The Treatment Of Hypereosinophilic Syndrome 2012 ·Journal of Allergy and Clinical Immunology ·Amy D. Klion, Florence Roufosse, Jean‐Emmanuel Kahn, Gerald J. Gleich, Lawrence B. Schwartz, (unknown), Lanny J. Rosenwasser, Judah A. Denburg, Johannes Ring, Marc E. Rothenberg, (unknown), (unknown), (unknown), D. C. Templeton, Héctor Ortega	1
14	Status of Asthma Control in Pediatric Primary Care: Results from the Pediatric Asthma Control Characteristics and Prevalence Survey Study (ACCESS) 2010 ·The Journal of Pediatrics ·Andrew H. Liu, Alicia Gilsenan, Richard H. Stanford, William R. Lincourt, Ryan Ziemiecki, Héctor Ortega	56
15	Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life 2009 ·Annals of Allergy Asthma & Immunology ·Heather M. Edin, (unknown), (unknown), Catherine Scott-Wilson, (unknown), Héctor Ortega	3
16	β2-Receptor Polymorphisms in Patients Receiving Salmeterol with or without Fluticasone Propionate 2009 ·American Journal of Respiratory and Critical Care Medicine ·Eugene R. Bleecker, Harold S. Nelson, Monica Kraft, Jonathan Corren, Deborah A. Meyers, Steven W. Yancey, Wayne H. Anderson, Amanda Emmett, Héctor Ortega	81
17	Needs and Opportunities for Research in Hypersensitivity Pneumonitis 2005 ·American Journal of Respiratory and Critical Care Medicine ·Jordan N. Fink, Héctor Ortega, Herbert Y. Reynolds, Yvon Cormier, Leland L. Fan, Teri J. Franks, Kathleen Kreiss, Steven L. Kunkel, David A. Lynch, Santiago Quirce, Cecile S. Rose, Robert P. Schleimer, Mark Schuyler, Moisés Selman, Douglas Trout, Yasuyuki Yoshizawa	129
18	Future Research Directions in Asthma 2004 ·American Journal of Respiratory and Critical Care Medicine ·(unknown), Susan Banks‐Schlegel, Patricia Noël, Héctor Ortega, Virginia Taggart, Jack A. Elias	52
19	Use of Specific Inhalation Challenge in the Evaluation of Workers at Risk for Occupational Asthma 2002 ·CHEST Journal ·Héctor Ortega, David N. Weissman, (unknown), Daniel E. Banks	35
20	Evaluación de un programa de rehabilitación del paciente esquizofrénico 1998 ·(unknown), (unknown), Héctor Ortega, (unknown), Marcelo Valencia, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact